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ABSTRACT 
It is well recognized that cancers develop and grow as a result of disordered function of tumor 
suppressor genes and oncogenes, which may be exploited for screening purposes. Extensive 
evidence indicated tumor suppressor protein p53 as candidate marker for mutation identifica-
tion. We have investigated mutant p53 protein expression in human breast tumors in relation 
to antioxidant status deficiency. The study included 100 breast cancer patients. p53 protein 
expression was evaluated by Western blot assay and immunostaining using a CM-1, DO-7 
and Pab240 antibodies. Antioxidant parameters and lipid peroxidation were estimated by bio-
chemical analyses. Western blotting with epitope-specific monoclonal antibody Pab240 
strongly suggests that nuclear extracts from breast cancer cells express mutant forms of p53. 
It is of interest that the mutant forms of p53 overexpression in conjunction with the appear-
ance of nuclear bodies are observed in highly aggressive carcinomas. Expression of isoform 
Δp53 (45 kDa) and isoform of ~ 29 kDa were more common in cases with LN metastasis. 
These studies point out the molecular consequences of oxidative stress (lipid peroxides, LP, 
p<0.001) and antioxidant status deficiency (copper, zinc superoxid dismutase, SOD, p<0.001; 
catalase, CAT, p<0.01; glutathione reductase, GR, p<0.001; glutathione, GSH, p<0.05) and 
indicate the importance of p53 mutation as the commonest genetic alteration detected in 
breast cancer cells. The expression of mutant p53 is correlated to increased lipid peroxides 
(0.346, p<0.05 ) and lowered antioxidant activity of CAT (- 0.437, p<0.01) in the breast can-
cer patients.  
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INTRODUCTION 
The loss of wild-type p53 gene expres-
sion has exceptionally been implicated in the 
development of a wide variety of human 
cancers and it is generally accepted that p53 
is a component in biochemical pathways 
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central to human carcinogenesis (Braithwaite 
and Prives, 2006). Although the role of the 
p53 gene in cancer genesis and development 
has fueled as many questions (Levine et al., 
2006; Meek, 2009), study of p53 has come to 
the forefront of cancer research and detection 
of its abnormalities during the development 
of tumors may have diagnostic, prognostic 
and therapeutic implications (Royds and 
Iacopetta, 2006). To be of value in clinical 
practice, immunohistochemical assessment 
of p53 protein should provide clinically rele-
vant information. The degree of concordance 
between p53 gene mutation and the accumu-
lation of p53 protein cannot be perfect, how-
ever, the immunohistochemical assay using 
anti-p53 antibodies is the most widely appli-
cable approach for detection of tumors in 
routine investigations, particularly with re-
gard to diagnosis or prognosis. The current 
study has extended the previous analyses in 
order to characterize potential association of 
AO status deficiency with breast cancer. As 
a working hypothesis, we proposed that ma-
lignant transformation, antioxidant status de-
ficiency and oxidative stress are closely con-
nected. Detection of p53 mutations may also 
be of interest of help identifies early lesions 
that are at a high risk of malignant evolution, 
particularly in tumors where p53 mutation is 
considered as an early event. Specifically, in 
breast cancer detection of a mutation in a 
dysplastic lesion may be considered as an 
indicator of high risk of malignant transfor-
mation. In addition, the identification of a 
mutation may help to determine the clonality 
of a tumor in patients with multiple lesions, 
and to characterize recurrence as well as dis-
tant metastasis. This approach, which has 
been implemented in the following guide-
lines, is based on the model proposed by 
Gannon et al. (1990) that the different acti-
vating mutations exert a common conforma-
tional effect which results in expression of 
the Pab240 epitope on mutant p53 mole-
cules.  
P53 becomes phosphorylated in response 
to various cellular stresses, including reac-
tive oxygen species (ROS), which can result 
in cell cycle arrest, and in some cases leads 
to apoptosis. While the apoptotic response to 
p53 is linked to ROS-dependent activation of 
p53, basal p53 expression drives a number of 
antioxidant (AO) responses that can limit 
oxidative stress (Liu et al., 2008; Ladelfa et 
al., 2011). P53 induces a range of AO targets 
such as GPx1, MnSOD, ALDH4 and 
TPP53INP1 (Budanov et al., 2010; Pani and 
Galeotti, 2011). P53 protein in the breast 
may function as a sensor of oxidative stress 
and its up-regulation in response to cellular 
(oxidative) stress is suggested to be a cyto-
protective response (Hofseth et al., 2004; 
Staib et al., 2005). Oxidative stress is con-
sidered to be implicated in the etiology of 
cancers including breast (Grek and Tew, 
2010; Kryston et al., 2011; Ambrosone, 
2000), while in the primary cancer site may 
increase the likelihood of angiogenesis (Xia 
et al., 2007) and metastasis (Pani et al., 
2010). Since oxidants were shown to be mu-
tagenic and may participate in the activation 
of proto-oncogenes and the inactivation of 
tumor suppressor genes (Schiff et al., 2000; 
Hussain et al., 1994) in this work we esti-
mated the association between mutant p53 
proteins, oxidative stress and AO protection 
in breast cancer. Therefore, we explored the 
concentration of lipid hydroperoxides (LP), 
as well as AO enzyme activities of copper, 
zinc superoxid dismutase (CuZnSOD), cata-
lase (CAT), glutathione peroxidase (GPx), 
glutathione reductase (GR) and the level of 
glutathione (GSH) in the blood of patients 
with primary breast carcinoma. We also ex-
plored the relation between activity and pro-
tein level of CuZnSOD since previously was 
shown that increased levels of O2•− and 
H2O2 are involved in breast cancer (Ray et 
al., 2000; Yeh et al., 2005). We expect that 
these analyses may provide more insight into 
how the knowledge of the cellular p53 pro-
tein expression and antioxidant status can 
help to improve the management of breast 
cancer. 
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MATERIALS AND METHODS 
Reagents 
All reagents were purchased from Sigma 
(St. Louis, MO, USA), and Merck (Darm-
stadt, Germany). Assays for CuZnSOD, 
GPx, GR, GSH and LP were purchased from 
Oxis Bioxytech Assays (Oxis International 
Inc., Portland, OR, USA). Rabbit anti-
CuZnSOD polyclonal antibody (SOD-100) 
and alkaline phosphatase-conjugated goat 
anti-rabbit IgG (SAB-301) were purchased 
from Stressgen Biotechnologies (Victoria, 
Canada). Rabbit anti-human p53 polyclonal 
antibody (CM-1) was purchased from Dr. 
Midgley (University of Dundee, United 
Kingdom). Biotinylated swine anti-rabbit Ig 
serum (E-353), mouse anti-human p53 mon-
oclonal antibody (clone DO-7, M-7001), bio-
tinylated rabbit anti-mouse antibody (E-354) 
and ABComplex-HRP (K-377) were pur-
chased from Dako Denmark (Glostrup, 
Denmark). Monoclonal antibody Pab240 (sc-
99), HRP-conjugated rabbit anti-mouse IgG 
(sc-358917) and rabbit anti-actin antibody 
(C-11: 1615) was purchased from Santa Cruz 
Biotechnology (Santa Cruz, CA, USA). 
HRP-conjugated goat anti-rabbit IgG (SAB-
301) were purchased from Millipore (Billeri-
ca, MA 01821, USA). Human breast carci-
noma cell line (CL-239M) was purchased 
from BioGenex (Fremont, CA, USA).  
 
Subjects and breast cancer samples 
The study included 100 breast cancer pa-
tients (age in years: median=56, min=32, 
max=86) from the Institute of Oncology and 
Radiology of Serbia, Belgrade, Serbia. All 
patients were newly diagnosed and tumors 
were clinically categorized as stage I (6 cas-
es), stage II (40 cases), stage III (51 cases) 
and stage IV (3 cases) according to the clas-
sification of the International Union Against 
Cancer (UICC, 1997). Primary breast cancer 
cases were classified according to TNM 
classification and tumors were histologically 
diagnosed as ductal (72), lobular (21), tubu-
lar (4) and medullary (3) type. During the 
study period patients were not submitted to 
endocrine, chemo- or radiotherapy. Ten 
normal breast tissues were selected from 
macroscopically normal areas and 6 from 
non-tumor patients. Blood samples from six-
ty healthy women were used as controls for 
the measurements of AO parameters and LP 
(age in years: median=54, min=34, max=80). 
The patients and the controls were nonsmok-
ers, and they used no alcohol consumption, 
hormones, oral contraceptives, or dietary 
supplements with antioxidants. None of the 
subjects had concomitant diseases such as 
diabetes mellitus, rheumatoid arthritis, liver 
disorders or any other malignancies. Accord-
ing to the ethical guidelines of the Helsinki 
Declaration, informed consent was obtained 
from all participants and the protocol used in 
this study was approved by the Ethics Com-
mittee of Institute of Oncology and Radiolo-
gy of Serbia, University of Belgrade, Bel-
grade, Serbia. 
 
Tissue and cellular fractionation  
The normal and cancer tissues were sur-
gically dissected and frozen. The nuclear 
fraction of normal and tumor tissues were 
obtained by differential centrifugation 
(Blobel and Potter, 1966). Briefly, the sam-
ples of normal and neoplastic tissue were 
minced by fine dissection and homogenized 
in 0.25 M sucrose, 5 mM MgCl2, 0.5 % Tri-
ton X-100, 1 mM phenylmethylsulfonylfluo-
ride (PMSF) and 50 mM Tris-HCl, pH 7.4, 
followed by centrifugation of the homoge-
nate at 800 x g for 10 min (Sorvall RC-5B, 
Sorvall Ltd., Stevenage, England). The su-
pernatants were spun at 11000 x g at 4 °C for 
25 min and the resulting supernatant was 
again centrifuged at 20000 x g, at 4 °C for 
45 min (Beckman L7-55 centrifuge, Beck-
man Instruments Inc., Palo Alto, CA, USA). 
The cytosolic fraction was obtained by fur-
ther centrifugation of supernatant at 100000 
x g, at 4 °C for 60 min. The pellet obtained 
after first centrifugation was homogenized in 
ice-cold buffer (2.2 M sucrose, 5 mM 
MgCl2, 0.5 % Triton X-100, 1 mM PMSF 
and 50 mM Tris-HCl, pH 7.4) and further 
purified by centrifugation. After this step the 
pellets representing the soluble nuclear pro-
teins were resuspended in 0.25 M sucrose, 
5 mM MgCl2, 0.5 % Triton X-100, 1 mM 
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PMSF and 50 mM Tris-HCl, pH 7.4. Protein 
content in the nuclear fraction was deter-
mined by the method of Lowry et al. (1951), 
using bovine serum albumin as a reference, 
and samples were aliquoted and stored 
at -20°ºC. 
 
Western blot analysis of p53 
Proteins isolated from normal and breast 
cancer cells were suspended in sample load-
ing buffer (0.1 M Tris, pH 6.8, 20 % glycer-
ol, 4 % SDS, 0.04 % bromphenolblue, 10 % 
β-mercaptoethanol) and separated electro-
phoretically according to procedure of 
Laemmli (1970). Equal amounts of nuclear 
proteins (50 μg) per line were loaded and run 
on 12  % SDS-polyacrylamide gels using a 
Mini-Protein® III Electrophoresis Cell (Bio-
Rad Laboratories Inc., Hercules, CA, USA). 
Separated proteins were transferred onto ni-
trocellulose membrane (Amersham Hybond, 
GE Healthcare Bio-Sciences AB, Uppsala, 
Sweden) according to the procedure of Tow-
bin et al. (1979). Transfer of proteins from 
the acrylamide gel to nitrocellulose was per-
formed in transfer buffer (25 mM Tris, 
192 mM glycine, 0.1 % SDS, 20  % metha-
nol, pH 7.5) at 30 V, 40 mA overnight at 
4 °C (Trans-Blot® SD Electrophoretic 
Transfer Cell, Bio-Rad Laboratories Inc., 
Hercules, CA, USA). Nitrocellulose filters 
were blocked overnight with blocking buffer 
(1 % BSA in 50 mM Tris, 0.9 % NaCl, 
0.05 % Tween 20, pH 7.5). The filters were 
then incubated for 1 h 45 min in buffer (50 
mM Tris, 0.9 % NaCl, 0.05 % Tween 20, pH 
7.5) plus primary antibody CM-1 at the op-
timal dilution 1:1000. The CM-1 antibody is 
a rabbit high-titre polyclonal antiserum 
raised against human recombinant wild-type 
p53 protein (Midgley et al., 1992). After 1 h 
of incubation with the biotinylated swine an-
ti-rabbit Ig serum (diluted 1:1000) and strept 
AB Complex-HRP conjugated (diluted 
1:100) the protein bands were visualized in a 
HRP substrate diaminobenzidine tetrahydro-
chloride (DAB). The same membranes were 
stripped and probed for β-actin (dilution 
1:10000) as an internal loading control. To 
detect actin with rabbit polyclonal antibody 
we used the HRP-conjugated goat anti-rabbit 
(1:2000) antibodies as secondary antibodies. 
Reproducibility was assessed by repeating 
the protein extraction and the SDS-PAGE 
three times. 
The primary mAb Pab240 was detected 
with HRP-conjugated rabbit anti-mouse Ig 
antiserum (diluted 1:50) and diaminobenzi-
dine substrate. It is important to note that the 
Pab240 is a mAb recognizing an epitope 
specifically exposed on the p53 protein in an 
altered-mutated conformation (Gannon et al., 
1990). It has been shown that Pab240 anti-
body recognizes mutant forms of p53 in a 
wide range of species by cell staining and 
immunoblotting (Gannon et al., 1990). The 
epitopes for the Pab240 antibody was 
mapped between amino acids 213-217 (Ste-
phen and Lane, 1992).  
 
Immunohistochemical analysis 
Immunohistochemical (IHC) staining 
was performed on 3 μm tissue sections by an 
avidin-biotin-peroxidase complex (ABC) 
technique (Hsu et al., 1981) using both fro-
zen and formalin-fixed, paraffin-embedded 
tissues. For formalin-fixed, paraffin-embed-
ded sections, we applied the microwave oven 
heating technique, shown to be effective for 
the retrieval of masked epitopes of many an-
tigens. The primary antibodies used were 
mouse monoclonal antibody (clone DO-7) 
recognizing a denaturation-resistant epitope 
between amino acids 35 and 45 and has been 
shown to recognize both the wild-type and 
mutant forms of p53 protein (Vojtesek et al., 
1992). In addition, IHC with p53 antibodies 
CM-1 and Pab240 was performed. Briefly, 
after dewaxing, endogenous peroxidase ac-
tivity was blocked by incubating the sections 
with methanol containing 3 % hydrogen per-
oxide for 20 min. After preincubation with 
normal rabbit serum (diluted 1:5) for 20 min, 
a three-step immunoperoxidase procedure 
was applied: first with the primary antibodies 
DO-7 at the appropriate working dilution 
1:50 in 0.1 % BSA overnight at 4 °C, second 
with biotinylated rabbit anti-mouse immuno-
globulin (diluted 1:250 in 0.1 % BSA) for 
one hour at room temperature, and the third 
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with strept ABComplex-HRP (diluted 1:100) 
for 40 min. Finally, the sections were visual-
ized by incubation with diaminobenzidine 
tetrahydrochloride (DAB) in hydrogen per-
oxide substrate with 50 mg of imidazole for 
10 min. The sections were counterstained 
with methyl green (0.5 %, 2 min) or Harris 
haematoxylin to visualize nuclei. We also 
used the alkaline phosphatase anti-alkaline 
phosphatase (APAAP) immunohistochemi-
cal technique (Cordell et al., 1984). Negative 
control slides were processed with each slide 
run and excluded the primary antibody but 
included all other steps of the procedure. A 
human breast carcinoma cell line, which ex-
presses p53 suppressor gene product, is used 
as the positive control. The IHC staining was 
semiquantitatively scored by 2 of the au-
thors. We studied the tissue samples by as-
sessing the site of staining, the proportion of 
cell staining (counting at least 1000 cells/ 
sample) and the intensity of staining: weak 
(1+), moderate (2+), or strong (3+). Scoring 
was as follows: 1 % - 10 % tumor cell nuclei 
staining for p53=1+; 11 % - 30 % tumor cell 
nuclei staining for p53=2+; 31 % - 50 % tu-
mor cell nuclei staining for p53=3+; > 50 % 
tumor cell nuclei staining for p53=4+. 
 
Blood samples 
Blood samples were obtained after an 
overnight fast by venous arm puncture in 
lithium-heparinized tubes. Blood plasma and 
blood cell preparations used for measure-
ments of LP and AO parameters were pre-
pared from native and in vitro cultured blood 
according to previously described procedures 
(Kasapović et al., 2010). 
 
Assay of SOD activity 
SOD-525™ assay is based on SOD-me-
diated enhance of autoxidation of 5,6,6a,llb-
tetrahydro-3,9,10-tryhydroxybenzo[c]fluorene 
in aqueous alkaline solution to produce a 
chromophore with the absorbance maximum 
at 525 nm (Perkin Elmer spectrophotometer, 
λ25, Perkin Elmer Instruments, Norwalk, 
CT, USA). The activity of SOD is calculated 
from the proportion of the autoxidation rates 
in the conditions of SOD presence (Vs) and 
absence (Vc). One SOD-525 activity unit is 
defined as the activity that doubles the rate 
of autoxidation in the control blank 
(Vs/Vc=2).  
 
Assay of CAT activity 
CAT activity was measured by the meth-
od of Beutler (Beutler, 1984), as the rate of 
H2O2 decomposition by CAT contained in 
the examined samples. The reaction was car-
ried out in an incubation mixture containing 
1 M Tris–HCl, 5 mM EDTA, pH 8.0 and 
monitored spectrophotometrically at 230 nm. 
One CAT activity unit is defined as 1 μmol 
of H2O2 decomposed per minute under the 
assay conditions. 
 
Assay of GPX activity 
The principle of GPx-340™ assay is that 
oxidized glutathione (GSSG) formed during 
reduction of an organic peroxide by GPx, is 
immediately regenerated to its reduced form 
(GSH) with associated oxidation of NADPH 
to NADP+. The oxidation of NADPH was 
monitored spectrophotometrically as a de-
cline in absorbance at 340 nm. One GPx-340 
activity unit is defined as 1 μmol of NADH 
oxidized per minute under the assay condi-
tions. 
 
Assay of GR activity 
The principle of GR-340™ assay is that 
oxidation of NADPH to NADP+ during the 
reduction of oxidized glutathione (GSSG) is 
catalyzed by a limiting concentration of GR. 
The oxidation of NADPH was spectropho-
tometrically measured as a decline in ab-
sorbance at 340 nm. One GR-340 activity 
unit is defined as 1 μmol of NADH oxidized 
per minute under the assay conditions. 
 
GSH concentration 
GSH-420™ assay is based on the reac-
tion of 4-chloro-1-methyl-7-trifluoromethyl-
quinolinium and all thiols to produce thio-
ethers. Following the increase of pH above 
13 by addition of base, a β-elimination spe-
cific to the GSH-thioether produces the 
chromophoric thione, measured spectropho-
tometrically at 420 nm. 
EXCLI Journal 2014;13:691-708 – ISSN 1611-2156 
Received: April 14, 2014, accepted: June 12, 2014, published: June 23, 2014 
 
 
696 
Lipid hydroperoxide concentration 
The principle of LPO-560™ assay is that 
under acidic conditions, hydroperoxides 
promote oxidation of Fe2+ to Fe3+ ions 
which binds the indicator xylenol orange and 
produces a colored complex measured spec-
trophotometrically at 560 nm. Since biologi-
cal samples have much higher content of 
H2O2 than that of other hydroperoxides, pre-
treatment with CAT decomposed the exist-
ing H2O2 and eliminated the interference.  
 
Protein concentration 
Determination of protein concentration 
was performed by the method of Lowry et al. 
(1951).  
 
Western blot analysis of CuZnSOD 
Equal amounts of protein were dissolved 
in SDS-PAGE sample loading buffer and 
subjected to SDS-PAGE electrophoresis in 
10 % polyacrylamide gel (Mini-protean®3 
Cell, Bio-Rad Laboratories Inc.) (Laemmli, 
1970). Separated proteins were transferred to 
nitrocellulose membranes for Western blot 
analysis of CuZnSOD (Trans-Blot® SD 
Semi-Dry Electrophoretic Transfer Cell, 
Bio-Rad Laboratories Inc.). Non-specific 
binding sites on membranes were blocked 
with TBST (10 mM Tris, 150 mM NaCl, 
0.1 % Tween 20) containing 1 % BSA and 
then exposed to rabbit anti-CuZnSOD poly-
clonal antibody and rabbit anti-actin anti-
body. For detection purposes we used alka-
line phosphatase-conjugated goat anti-rabbit 
IgG. Reproducibility was assessed by repeat-
ing the SDS-PAGE and blotting three times. 
The density of bands was determined by Im-
ageJ processing program, normalized to the 
level of actin and expressed as percent of 
value found in the control samples consid-
ered as 100 %. 
 
Statistical analysis 
The significance of differences between 
different experimental values was assessed 
by means of ANOVA, Student’s t-test and 
Pearson’s product moment correlation. Data 
were tested at a statistical significance level 
of p<0.05 and expressed as mean±SEM. All 
statistical manipulations were performed us-
ing the SPSS for Windows Software System 
and OriginPro 8.0. 
 
RESULTS 
Expression of p53 protein in breast  
carcinoma: immunohistochemistry  
and Western blot analysis 
Forty-seven cases of breast cancer were 
screened for the presence of the p53 protein 
by immunohistochemical and Western blot 
assay using a polyclonal antiserum CM-1 or 
monoclonal antibodies DO-7 and Pab240 
with multiple anti-p53 specificities. The ma-
jority of the immunohistochemical studies 
used either DO-7 or Pab240 as the antibody 
for identifying abnormal accumulation of 
p53 and so results for these antibodies are 
shown separately. A positive staining was 
observed in 30/47 (64 %) specimens with 
variations in the staining percentage and in-
tensity. Three groups were detected: 25 cases 
(53 %) had high levels of p53 in the nucleus 
of the cancer cells (Figure 2a; 3a,b; 4a), 17 
cases (36 %) had a complete lack of detecta-
ble staining (Figure 3c) and 5 cases (11 %) 
showed a pattern of cytoplasmic and nuclear 
staining. In 2 cases, a strong nuclear and 
weaker cytoplasmic localization of p53 was 
observed (Figure 2a). The same breast cancer 
(Figure 3a and b) gave strong nuclear stain-
ing with Pab 240 (Figure 4a). Surprisingly, 
17 specimens (36 %) showed complete ab-
sence of detectable p53 protein in multiple 
sections despite the presence of abundant 
malignant tissue. Normal levels of p53 pro-
tein present in stromal cells, or in normal 
breast epithelium were undetectable and thus 
served as internal control (Figure 1a). Con-
trol experiments that substituted normal 
mouse IgG or phosphate-buffered saline for 
the p53-specific monoclonal antibody 
showed no detectable staining. IHC data ver-
ified the difference in the localization pat-
terns of the p53 wt forms and/or their mu-
tants. Moreover, the localization of the p53 
protein and each of the mutants differs sig-
nificantly in various breast cancer cells, sug-
gesting a multipotent role of the protein 
when it comes to activation pathways and 
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localization patterns within the cell. In fact, 
immunohistochemical detection of mutant 
forms of p53 overexpression results in exten-
sive mammary epithelial cell hyperplasia and 
a disorganized basement membrane, all fea-
tures associated with malignancy. The higher 
expression levels of mutant forms of p53 
protein in most breast cancer analyzed was 
associated with more frequent lymph node 
metastasis. We observed a significant differ-
ence for the progression of the disease be-
tween p53-positive tumors and p53-negative 
tumors (Student’s t-test, p<0.01). In general, 
tumor p53 overexpression correlates with a 
more aggressive tumor phenotype and nega-
tive survival prognosis. As expected, the 
MAbs DO-7 and Pab240 appears as a good 
marker for recognition of p53 mutated cases 
including those with a worse prognosis (Fig-
ure 1b; Figure 2a). 
P53 proteins overexpressed ectopically 
form a subnuclear structure. It is noteworthy 
that positive immunostaining of p53 is in 
conjunction with the appearance of nuclear 
bodies (Figure 2a; 3a, b; 4a). Nuclear bodies 
display punctate patterns suggesting p53 and 
additional proteins co-localized in the nucle-
ar bodies which were not seen in control 
cells. The nuclear body structure was detect-
ed in a high percentage of p53 positive cells 
but not in a small population of cells which 
stained negatively for p53 (Figure 2a; 3a, b; 
4a), and is a general phenomenon of the pro-
teins co-expression. Additionally, it is possi-
ble that anti-p53 antibodies cross-react with 
structurally similar epitopes on unrelated 
molecules. 
The expression of p53 detected by West-
ern blotting was compatible with the results 
of immunohistochemistry in most cases ex-
amined. Immunoreactive proteins were visu-
alized in nuclear extracts of breast carcinoma 
cells (Figure 2b, c; 4b). As indicated, the an-
ti-p53 antibody detected one band with the 
classical molecular mass of 53 kDa and an-
other at 45 and 29 kDa (Figure 2b). Truncat-
ed protein representing the p53 can be seen 
by smaller size of the 45- and 29-kDa (Fig-
ure 2b, Lane 1, 2). Notably, Western blot 
analysis with a p53 specific antibody CM-1 
revealed three closely spaced bands migrated 
at 36-45 kDa (Figure 2c, Lane 1). Expression 
of p53 and its isoforms Δp53 (45 kDa) and 
isoform of ~ 29 kDa were more common in 
cases with LN metastasis (Figure 2b, Lane 1, 
2). Taken together, these results indicate that 
in nuclear extracts of breast carcinoma cells 
p53 exists in various assemblies, with the 
smallest oligomer being a threemer. Western 
blotting with epitope-specific monoclonal 
antibody Pab240 strongly suggests that nu-
clear extracts from breast cancer cells ex-
press mutant forms of p53 (Figure 4b). 
 
 
 
 
Figure 1: p53 immunostaining in normal 
breast tissue and breast carcinoma  
(a) Normal breast tissue is negative for 
p53 
(b) Positive p53 immunostaining in the 
epithelial cancer cells using the anti-p53 
mAb DO-7. A mutant case with intense 
nuclear staining. 
Immunoperoxidase staining with nuclear 
counterstain with hematoxylin. Magnifi-
cation, x 40. Microwave antigen retrieval 
was for 15 min. 
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Figure 2: (a) Carcinoma of the 
breast with immunohistochemical 
evidence of p53 overexpression. 
Intense nuclear staining is evident. 
P53 associates with nucleolar 
structures.  
Frozen section was stained with 
anti-p53 antibodies DO-7 by the 
immunoperoxidase technique, with 
hematoxylin counterstain. Magnifi-
cation, x 250. 
(b) Western blotting analyses of 
p53 expressed in nuclear extracts 
of breast carcinoma cells. As indi-
cated, the anti-p53 antibody detect-
ed one band with the classical mo-
lecular mass of 53 kDa and another 
at 45 and 29 kDa. Truncated pro-
tein representing the p53 can be seen by smaller size. 
Proteins in nuclear extracts were resolved on a 12 % SDS-PAGE and then transferred to a nitrocellu-
lose membrane. p53 present in the nuclear extract were detected with CM-1 antibody (see Materials 
and methods). This experiment was repeated in triplicate with reproducible results. Lane 1, 2- breast 
cancer cases  
(c) Western blot analysis shows that p53 in nuclear extracts of breast cancer cells also migrated as 
three closely spaced bands at 38-45 kDa (Lane 1). The arrow indicates a single immunoreactive band 
representing p53 (Lane 3). Molecular mass markers are presented on the right.  
Procedures for SDS-PAGE and Western blot analyses were the same as those used for the experi-
ment described in Figure 2b, and detailed in Materials and methods. Each analysis was repeated 
three times with similar results. Lane 1, 2 and 3- breast cancer cases; Lane 4, 5- normal breast tissue 
 
 
Figure 3: Immunohistochemical analysis of p53 pro-
tein expression in carcinoma of the breast 
(a) A breast tumor displaying a more generalized and 
intense p53 nuclear staining. A diffuse pattern of stain-
ing was identified in the cytoplasm of tumor cells. The 
labelled cells for the p53 show a brown precipitate, a 
green staining underlines nuclei of unlabelled cells. 
(b) The positive cases demonstrated characteristic 
staining patterns that were either predominantly nu-
clear or both nuclear and cytoplasmic. P53 is located 
at the cytoplasmic surfaces of the nuclear envelope. 
Different structural systems of the nucleus are targets 
for p53. Nuclear p53 is found in the nucleoplasm, 
chromatin fraction and also attached to the nuclear 
matrix. Insert: focal staining showing the fine nucleolar 
distribution characteristic of p53. DAB staining is prev-
alent throughout the nuclear bodies. 
(c) Breast carcinoma cells show negative staining for 
p53. Unlabelled nuclei show only counterstain, indi-
cated by the blue color. 
Avidin-biotin immunoperoxidase technique on frozen 
sections counterstained with methyl green (a, b) or 
haematoxylin (b insert, c). All panels were photo-
graphed at the same magnification. 
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Figure 4: (a) Immunohistochemical detection of mutant forms of p53 in breast cancer cells 
High-power view showing granular staining pattern confined to nuclei. The epithelial levels contain 
cells with enlarged, darkly stained, irregularly shaped, dysplastic nuclei. Even among the positive cells 
the strength of staining was quite variable. Different structural systems of the nucleus are targets for 
p53. Nuclear bodies display punctuate patterns. 
P53 was immunostained with Pab240 antibody (diluted 1:50) using the avidin-biotin-peroxidase com-
plex (ABC) method. The appropriate secondary antibodies were diluted 1:200, and histochemical de-
tection was done by developing with aminoethylcarbazole. Nuclei were counterstained with hematoxy-
lin. Frozen tumor sample (magnification, x 320).   
(b) Western blot analysis of p53 expressed in the nuclear extract of breast cancer cells. 
A single immunoreactive band representing the mutant forms of p53 were visualized in nuclear ex-
tracts of breast carcinoma cells (Lane 1, 2). The p53 protein of relative molecular mass 53kDa, was 
absent in normal breast (Lane 3). 
Equal amounts of nuclear proteins (50μg/lane) from extracts of normal and breast cancer tissues were 
separated on 12 % SDS-PAGE and transferred to nitrocellulose membrane. The primary mAb Pab240 
was detected with HRP-conjugated rabbit anti-mouse Ig antiserum (diluted 1:50). The reactive pro-
teins were visualized with diaminobenzidine (DAB) as chromogen. Bottom panel shows actin loading 
control. Lane 1, 2- invasive ductal breast carcinomas. Lane 3- normal breast tissue 
Molecular mass markers are presented on the right. These results are representative of three experi-
ments. 
 
 
 
Antioxidant parameters and lipid  
hydroperoxides 
In the blood cells of native blood, AO pa-
rameters of breast cancer patients were found 
to decrease when compared to age-matched 
controls (Figure 5). The decline of enzyme 
activities were recorded for SOD (p<0.001), 
CAT (p<0.01) and GR (p<0.001), whereas 
GPx activity was found to be unchanged 
(p>0.05). This was followed with the decline 
of GSH (p<0.05) and the increase of LP con-
centrations (p<0.001). 
The decline of CuZnSOD activity 
(p<0.001) and concentration of GSH 
(p<0.01) in breast cancer patients were the 
only effects which were maintained after 
48 h of in vitro blood incubation, while the 
effects on CAT (p>0.05) and GR (p>0.05) 
activities, detected in native blood, disap-
peared (Figure 6). Prolonged decline of 
CuZnSOD activity was indication for the 
change in protein synthesis of this enzyme. 
The disappearance of effects on other AO 
enzymes in incubated blood is likely the 
consequence of different modulatory milieu 
of blood cells presented in native blood and 
incubation medium.  
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Figure 5: Antioxidant enzyme activities and con-
centration of GSH and lipid peroxides (LP) in 
native blood of control subjects (A) and breast 
cancer patients (B). The data are given in mean 
values ± SEM, *p<0.05, **p<0.01, ***p<0.001 
compared to A (Student’s independent t-test) 
 
 
Analysis of correlations between the ac-
tivities of AO enzymes or GSH concentra-
tion and the concentration of LP revealed 
negative correlation between the activity of 
CAT and concentration of LP (r = - 0.298, 
p<0.05) (Figure 7). 
CuZnSOD protein level was reduced in 
blood cells of breast cancer patients in native 
blood (p<0.05), as well as in incubated blood 
(p<0.05) when compared to healthy controls 
considered as 100 % (Figure 8). 
Analysis of correlations between the AO 
parameters or concentration of LP and the 
level of mutant p53 protein expression 
showed negative correlation for the activity 
of CAT (- 0.437, p<0.01) and positive corre-
lation for the concentration of LP (0.346, 
p<0.05) (Table 1). 
 
 
 
Figure 6: Antioxidant enzyme activities and con-
centration of GSH in in vitro incubated blood of 
control subjects (A) and breast cancer patients 
(B). The data are given in mean values ± SEM, 
**p<0.01, ***p<0.001 compared to A (Student’s 
independent t-test) 
 
 
DISCUSSION 
The p53 tumor suppressor gene has a 
critical role in the protection of the genome 
from the consequences of DNA damage and 
its inactivation is a critical step in cellular 
transformation. p53 serves as transcriptional 
regulator, genomic stabilizer, inhibitor of 
cell cycle progression, facilitator of apopto-
sis, and inhibitor of angiogenesis (Hollstein 
and Hainaut, 2010). Major variants of the 
p53 protein may be formed through alterna-
tive splicing of mRNA or protein cleavage. 
To date, the human p53 gene has been re-
ported to encode for nine different p53 pro-
teins (isoforms) through variously spliced 
mRNA (Bourdon et al., 2005; Rohaly et al., 
2005). These are the full-length proteins, 
three NH2-terminally truncated isoforms 
translated from an alternative point of initia-
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Figure 7: Data plot and coefficient of Pearson’s 
correlation r between the activity of CAT and the 
concentration of lipid peroxides (LP) in native 
blood of breast cancer patients 
 
 
Figure 8: Relative levels of CuZnSOD protein in 
native (a) and in vitro incubated (b) blood of con-
trol subjects (A) and breast cancer patients (B). 
Relative values are expressed as percent of val-
ue found in the control subjects, which is consid-
ered as 100 %. * p<0.05 compared to A (Stu-
dent’s independent t-test)  
 
tion at codon 40 or by alternative splicing of 
intron 2 (Bourdon et al., 2005; Courtois et 
al., 2002; Ghosh et al., 2004), two COOH-
terminally truncated isoforms produced by 
alternative splicing of intron 9 (Bourdon et 
al., 2005; Flaman et al., 1996), three iso-
forms produced from an internal promoter in 
intron 4 (Bourdon et al., 2005), and one iso-
form produced by alternative splicing within 
exons 7 to 9 (Rohaly et al., 2005). In addi-
tion, truncated p53 protein products are 
known produced as a result of protease ac-
tion most likely through an autoproteolysis 
mechanism (Okorokov et al., 1997). Howev-
er, it is also possible that some new p53 
isoforms arise due to mutations (Varley et 
al., 2001). Mutations in p53 gene and elevat-
ed levels of mutated forms of p53 protein in 
breast tumors suggesting that the deregulated 
p53 expression and reduced apoptosis may 
be important in breast tumor development 
(Zhou et al., 2009; Abdel-Fatah et al., 2010). 
P53 gene mutations are seen in all stages of 
breast cancers, from in situ lesions to inva-
sive carcinomas, suggesting that the p53 
gene alteration can occur in the earliest re-
cognized phase of breast cancer and that this 
alteration is maintained during tumor pro-
gression (Weigelt et al., 2003; Torres et al., 
2007; Suzuki and Tarin, 2007). Furthermore, 
mutations of the p53 gene seem to be associ-
ated with clonal evolution and metastatic 
progression of the disease (Weigelt et al., 
2005; Nicolini et al., 2006, 2007; Riethdorf 
et al., 2008). Abrogation of p53 function 
should therefore lead to a more aggressive 
breast cancer phenotype and a worse clinical 
outcome (Abdel-Fatah et al., 2008). Molecu-
lar analysis of the p53 gene is complex and 
poorly suited to routine diagnostic use: p53 
mutations have been found in 90 of the 393 
codons required for synthesis of the protein. 
This considerable heterogeneity makes diag-
nosis more difficult, because the region to be 
analyzed extends over virtually the entire 
gene. Many groups have focused their inves-
tigations on exons 5 to 8, which are the tar-
get of 80-90  % of all mutations. Mutations 
in exons 4 to 8 of the p53 gene were evaluat-
ed using PCR-SSCP sequencing analysis as 
described Olivier et al. (2006) and Shah et al. 
(2012). The vast majority of the TP53 muta-
tions detected in the earlier study by Angèle 
et al. (2000), are among those frequently 
found and are in accordance with the pub-
lished TP53 mutation spectra in breast can-
cer (IARC TP53 mutations database in breast 
tumors). The difficulty to link p53 mutation 
status to clinical outcome and cancer treat-
ment can be explained by the fact that muta-
tions of the p53 gene do not necessarily re-
sult in inactivation of p53 transcriptional ac-
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tivity. Hence, 60 % of the mutations that can 
occur in the p53 gene do not alter p53 tran-
scriptional activity. Only 15 % of the muta-
tions lead to mutant p53 completely inactive 
in transactivation. In the remaining 25 %, 
mutant forms of p53 present differential 
transcriptional activity. They can transacti-
vate some promoters, but are completely in-
active on others (Petitjean et al., 2007a, b). 
 
 
Table 1: Correlation between AO parameters or 
concentration of LP and expression of mutant 
p53 proteins  
 Mutant p53 
   r 
SOD   0.207 
CAT -0.437** 
GPx   0.090 
GR -0.109 
GSH -0.134 
LP   0.346* 
r – coefficient of Pearson's correlation 
* < 0.05, ** < 0.01 
 
In this study we used a panel of anti-p53 
antibodies CM-1, DO-7 and Pab240 for cell 
staining and found abnormalities in at least 
30 % of the cases. Based on the literature, 
DO-7 is one of the most sensitive for the de-
tection of p53 overexpression (Vojtesek et 
al., 1992). Other published data also support 
that rabbit p53 antibody CM-1 is highly sen-
sitive for the p53 staining (Midgley et al., 
1992). It is widely accepted that in normal 
tissues, p53 protein is present in such low 
quantities that it is not readily detectable by 
immunochemical techniques. Thus, the ac-
cumulation of p53 protein in normal breast 
epithelial cells is a highly unusual finding 
because the abnormally stabilized p53 pro-
tein has only been associated with malignant 
disease and DNA damage (Hollstein and 
Hainaut, 2010). It is thought that the mono-
clonal PAb240 antibody reliably detects a 
wide variety of p53 mutations and these mu-
tations have a common effect on the struc-
ture of p53. An antibody PAb240 does not 
immunoprecipitate wild-type p53 (Gannon et 
al., 1990). Based on the analysis of breast 
tumor samples, it became clear that DO-7 
and CM-1 antibodies are potentially useful in 
the detection of p53 overexpression. In ac-
cordance with the before mentioned data, the 
Pab240 antibody is extremely useful for the 
detection of p53 mutations of the type that 
occur in breast cancer.  
Western blotting analyses showed that 
the faster migrating forms of p53 are truncat-
ed version of the p53 protein, a Δp53 
(~ 45 kDa) and the isoform of ~ 29 kDa 
(Figure 2b). Understandably, as tetrameriza-
tion domain (residues 325-356) is preserved 
in Δp53 (Murray-Zmijewski et al., 2006), the 
p53 isoform has the ability to oligomerize. 
The oligomeric state of Δp53 in nuclear ex-
tracts of breast carcinoma cells (Figure 2c), 
suggesting that Δp53 may exert a functions, 
differential transcriptional activity per se in-
dependent from multi-functional transcrip-
tion factor p53, and a gene activation pattern 
different from that of p53 (Rohaly et al., 
2005). Additionally, that Δp53 does not in-
teract with p53 was confirmed by Western 
blot (Figure 2b, c). From the present results, 
we can conclude that out of the detected p53 
isoforms, (Bourdon et al., 2005; Bourdon, 
2007), Δp53 is the most easily identified iso-
form in nuclear extracts of breast carcinoma 
cells and the other isoforms are more diffi-
cult to identify. However, this should be in-
terpreted with cautions, as Bourdon et al. 
(2005) showed that p53β, p53γ and Δ40p53 
migrate all at 45 kDa. In this respect, the 45 
kDa band identified by Rohaly et al. (2005) 
is probably composed of a mix of Δp53, 
p53β, p53γ and Δ40p53. Δp53 is an alterna-
tive splice form that differs from the full-
length p53 form by lacking parts of exon 7, 
complete elimination of exon 8 and partial 
removal of exon 9 (Rohaly et al., 2005). The 
study of Baumbusch et al. (2006) is one of 
the first confirming that mRNA expression 
of both the full-length p53 and the Δp53 
form are elevated in tumors with missense 
and in frame mutations. The mRNA expres-
sion of p53 and Δp53 level showed a wide 
range in p53 wild-type tumors with signifi-
cant association to molecular breast cancer 
subtype distribution. Although our data sug-
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gests that p53 variants an ~ 45 and 29 kDa 
represent a minority of total cellular p53, a 
role for these isoforms cannot be discounted 
in view of their potential for interaction with 
p53-family member to alter the balance of 
p53, p63 and p73 transcriptional activities 
during normal and neoplastic cell growth. 
We should note that in the most tumor ana-
lyzed p53 levels were extremely low for de-
tection, as in the case of the tumor type 
shown (Figure 2c, Lane 2), suggesting dele-
tion, complex mutations generating stop co-
dons, overexpression of the p53 ubiquitin 
ligase MDM2, or wild-type p53 status. 
The three staining pattern of p53 protein 
(nuclear, nuclear and cytoplasmic and ab-
sent) have commonly been explained by the 
fact that mutant p53 proteins are more stable 
(have a longer half-life) than wild-type p53 
proteins. The non-detectable levels of p53 in 
the p53 negative tumors are either the very 
low wild-type levels or due to loss of p53 
(deletion mutants). In contrast, the elevated 
levels of nuclear and cytoplasmic p53 pro-
teins were previously thought to be mutant 
p53 proteins (Gannon et al., 1990). The high 
level of p53 protein seen in mutated tumors 
has previously been explained by accumula-
tion of the protein due to lack of degradation 
of the mutated protein and not by overex-
pression at the mRNA level (Royds and 
Iacopetta, 2006). Mutant forms of p53 in 
breast cancer cells may accelerate tumor 
progression under these circumstances via 
default of p53-mediated cell cycle arrest, 
DNA repair and/or apoptosis. It is now gen-
erally believed that different forms of mutant 
p53 proteins may have different functional 
and biological effects (Petitjean et al., 2007a, 
b; Vousden and Prives, 2005). All available 
information suggests that mutant forms of 
p53 are at a crossroad for multiple signaling 
pathways (Oren and Rotter, 2010). Further 
analyses of point and truncated mutant ex-
pression products of the p53 gene has shown 
that mutated forms of p53 not only lose their 
tumor suppressive functions but may also 
gain new abilities that enhance tumorigene-
sis (Oren and Rotter, 2010; Heinlein et al., 
2008; Adhikari and Iwakuma, 2009; Muller 
et al., 2009; Brosh and Rotter, 2009).  
Tumor derived p53 mutants act as trans-
activators of various cancer-associated genes 
in tumor progression. Indeed, the p53 muta-
tion is linked with chemo-resistance and 
transformation to a more aggressive disease 
in many tumor types (Al-Joudi et al., 2008). 
In the present study, we found that the higher 
expression levels of mutant p53 protein in 
most breast cancer analyzed was associated 
with more frequent lymph node metastasis, 
advanced TNM stage and poor survival 
which is consistent with other reports (Olivi-
er et al., 2006; Miller et al., 2005). A detailed 
overview of mutant form p53’s role in tumor 
formation is beyond the scope of this article 
and the reader is referred to several excellent 
reviews on this topic (Oren and Rotter, 2010; 
Adhikari and Iwakuma, 2009; Muller et al., 
2009). Clearly, p53 mutations impact on 
clinical outcome (Olivier et al., 2006), but it 
would be over-simplistic to assume that p53 
missense mutations are the sole contributors 
from the p53 network to the outcome of 
breast cancer. To date, attempts to group 
breast cancers according to p53 immuno-
histological phenotype have lagged behind 
transcriptional array approaches of tumor 
p53 transcriptional profiling (Miller et al., 
2005) and stroma profiling (Finak et al., 
2008), demonstrating significant association 
with outcome in breast cancer. The compari-
son of p53 mutation to immunohistochemis-
try in solid tumors initially identified pat-
terns of protein expression using p53, mdm2, 
mdm4 and p21, which in the 44 breast can-
cers examined closely, reflected the presence 
and class of p53 mutation (Nenutil et al., 
2005). Abdel-Fatah et al. (2010) have taken 
this further and hypothesize that the func-
tional status of p53 pathways, rather then 
p53 protein expression alone, could accurate-
ly discriminate between patients with good 
or poor outcome. Novel p53 isoforms sug-
gest alternative splicing as a regulatory fea-
ture of p53 activity. Importantly, it has also 
been reported that interactions between p53 
and its isoforms Delta40p53 or Delta133p53 
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play critical roles in intracellular signaling 
by ROS (Hafsi and Hainaut, 2011). 
Here we also demonstrated that the nu-
clear bodies formed by p53 although variable 
in size are clearly visible by light microsco-
py, which suggests that they likely contain a 
large number of additional proteins and are 
potentially associated with chromatin. As we 
exclude the possibilities that these nuclear 
bodies are nucleoli or nucleolus break-down 
products, one interpretation of these results 
is that the nuclear bodies are formed to regu-
late the sequence-specific transactivity of 
p53. Additionally, it is possible that they 
may function in a DNA synthesis or chroma-
tin structure-related events. Experimental 
evidence suggests that p53 may be directly 
involved in the regulation of DNA synthesis 
during either DNA replication or repair (Kim 
and Deppert, 2006; Gatz and Wiesmüller, 
2006; Vousden and Prives, 2009). Given 
their discrete and higher order structure, it is 
likely that p53 facilitates the formation of 
and associates with nuclear bodies. The in-
teraction between p53 and additional pro-
teins co-localized in the nuclear bodies is 
likely critical in the development of the neo-
plastic phenotype. In this regard, it is of note 
that mutations associated with the different 
forms of breast tumors are not only associat-
ed with alterations in oxidative stress but al-
so cell cycle alterations. Based on the find-
ings that in a more aggressive tumor pheno-
type mutant forms of p53 are localized into 
the nucleus in a form of nuclear bodies, this 
subnuclear structure may be a possible im-
munocytochemical biomolecular marker for 
the identification of this cancer type. Many 
forms of genotoxic stress can increase nucle-
ar bodies number and alter their biochemical 
composition suggesting that these character-
istic changes in nuclear bodies are likely a 
universal response to DNA damage (Dellaire 
and Bazett-Jones, 2004; Bernardi and Pan-
dolfi, 2007). 
Oxy-radicals were found to induce muta-
tions of hotspot codons 248 and 249 of hu-
man fibroblast p53 gene (Hussain et al., 
1994). The alteration of TP53 gene or post-
translational modification of p53 protein can 
alter its response to cellular stress. Based on 
this, hypothesis was made that the generation 
of oxygen and nitrogen species and alde-
hydes induce a high frequency of p53 muta-
tions in oxy-radical overload disease that 
may contribute to the increased risk of can-
cer (Hussain and Harris, 2006). Our results 
support this view, showing that expression of 
mutant p53 proteins associates with increase 
of oxidative damages and decrease of AO 
detoxifying capacity in breast cancer. Ele-
vated level of plasma LP (Figure 5) is in 
agreement with previous observations of el-
evated different lipid peroxidation products 
in the blood in those patients, such as 
TBARS (Kumaraguruparan et al., 2002a) 
and MDA (Gonenc et al. 2001). Diminished 
activities of SOD and CAT enzymes in 
blood cells (Figure 5) are also in accordance 
with previous records in erythrocytes and 
blood of breast cancer patients (Ray et al., 
2000; Kumaraguruparan et al., 2002a). Un-
der oxidative stress, elevated level of ROS 
can damage AO enzyme molecules, leading 
to their reduced activities (Kono and Fri-
dovich, 1982; Salo et al., 1988) and autoca-
talysis of oxidative damage process.  
Increased amounts of H2O2 produced by 
human tumor cells keeps them under persis-
tent oxidative stress (Szatrowski and Nathan, 
1991). Enlarged production of O2•− and 
H2O2 was also recorded in the blood of 
breast cancer patients independent of clinical 
stage of disease and menopausal status (Ray 
et al., 2000; Yeh et al., 2005). This may be 
due to decline of CuZnSOD and CAT activi-
ties (Figure 5) showing decreased capacity 
for O2•− and H2O2 detoxification in native 
blood of these patients. Lowered CAT activi-
ty correlating with an increase of LP concen-
tration (Figure 7), indicates elevated lipid 
peroxidation mediated by increased produc-
tion of H2O2. Since GPx activity in blood 
cells was unchanged in patients (Figure 5), it 
seems that oxidative damage is related most-
ly to suppressed activity of CAT. The lower 
GSH level in patients (Figure 5), supports 
the hypothesis that GSH status is inversely 
correlated to malignant transformation (Ku-
maraguruparan et al., 2002b). This may be 
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due to decreased GR capacity for GSH resto-
ration (Figure 5).  
Suppression of CuZnSOD activity has 
been the only prolonged effect of breast can-
cer on AO enzymes recorded after 48 h of 
blood incubation (Figure 6), indicating drop 
of SOD protein, which was confirmed by 
Western blot analyses in native, as well as in 
incubated blood (Figure 8). It seems that di-
sturbed expression of AO enzymes for O2•− 
and peroxides detoxification in human can-
cerogenesis, besides previously observed 
MnSOD (glioma) (Zhong and Oberly, 1997), 
and GPx (breast cancer) (Gromadziňska et 
al., 1997), includes CuZnSOD enzyme as 
well. Association between diminished CAT 
activity, increased oxidative damages and the 
expression level of mutant p53 forms (Figure 
7, Table 1), indicates H2O2 as most possible 
mediator of mutagenic impact on p53 in 
breast cancer, regarding its non-restricted 
diffusion mobility (Hussain et al., 2004) and 
involvement in signal transduction pathways 
(Finkel, 2011) and carcinogenesis (Am-
brosone, 2000). This is supported with recent 
findings of crucial function of CAT in p53-
mediated ROS regulation. p53 and its down-
stream targets physically and functionally 
cooperate with CAT causing p53 to express 
either antioxidant or prooxidant functions 
depending on stress intensity (Kang et al., 
2013). After genotoxic stress, high levels of 
p53 and p53-inducible gene 3 (IG3) cooper-
ate to reduce CAT activity and shift the in-
tracellular environment toward prooxidative 
conditions to induce apoptosis. Following 
this, it can be assumed that chronic oxidative 
stress in breast cancer, by inhibiting the de-
toxifying capacity for H2O2 and elevating the 
expression of mutant p53 proteins, disturb 
apoptotic interplay of p53, AO system and 
ROS contributing to breast carcinogenesis.  
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